NCT02575560View on ClinicalTrials.gov

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
EGFR-TKI Resistant Mutation
Interventions
OTHER

history data

history data of PFS after 1st line or second line theray

Trial Locations (1)

266042

Qingdao Central Hospital, Qingdao

All Listed Sponsors
lead

Qingdao Central Hospital

OTHER

NCT02575560 - Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter